Alnylam Pharmaceuticals Q3 Earnings Call Highlights

Alnylam Pharmaceuticals Q3 Earnings Call Highlights

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported third-quarter 2026 global net product revenue of approximately $1.3 billion, up 52% from a year earlier and 10% sequentially, as growth in its transthyretin, or TTR, franchise continued to drive results. Chief Executive Officer Yvonne Greenstreet said

Alnylam (ALNY) Q3 2026 Earnings Call Transcript

AMVUTTRA revenue jumped 65% year over year as TTR franchise momentum accelerates.

Alnylam falls despite earnings beats as US Amvuttra, Onpattro sales growth slows

Alnylam stock plunged after Q3 earnings beat as US Amvuttra demand slowed and costs rose. Read more here.

Alnylam Q3 Revenue Rises 17% to $1.46 Billion as Net Product Revenue Jumps 52%

Diluted non-GAAP EPS was $16.26. Alnylam reaffirmed its 2026 net product revenue forecast of $4.7 billion to $5.1 billion.